Studying cancer in pet dogs to find new treatments for human patients

Oct 13, 2009

A team of scientists at the National Cancer Institute (NCI) in Bethesda, USA, says that studying pet dogs with cancer could yield valuable information on how to diagnose and treat human cancers. In this week's PLoS Medicine, the team discusses an ongoing initiative in which spontaneously occurring cancers in dogs are being studied to help inform the development of new cancer drugs, devices and imaging strategies for human cancer patients.

Estimates suggest that as many as 1 million new diagnoses of cancer occur in in the United States each year. The condition is treated much like human cancer, with surgery, radiation, and chemotherapy. owners are often motivated to pursue novel and investigational treatments with their veterinarians.

The team of scientists at the Centre for Cancer Research at the NCI, led by Dr. Chand Khanna, believes that studying these new therapies in clinical trials with dogs may yield insights into how to improve care for human patients. Naturally occurring tumors in dogs have clinical and biological similarities to the human disease.

Khanna and colleagues say that a pet owner's decision to pursue an experimental therapy is influenced by a number of factors, especially the possible risks and benefits of the new therapy and the reduced costs for care provided by the investigational trial.

Additionally, they say, "many pet owners are motivated by the opportunity to contribute to the advancement of cancer treatment for future human and canine patients."

The study of and treatment in animals with naturally occurring cancers, known as comparative oncology, is not a new concept. Over the last 30-40 years investigators have used this approach to advance understanding and treatment of several human cancers, such as (osteosarcoma), lymphoma, and melanoma.

More information: Gordon I, Paoloni M, Mazcko C, Khanna C (2009) The Comparative Oncology Trials Consortium: Using Spontaneously Occurring Cancers in Dogs to Inform the Drug Development Pathway. PLoS Med 6(10): e1000161. doi:10.1371/journal.pmed.1000161

Source: Public Library of Science

Explore further: Orphan receptor proteins deliver 2 knock-out punches to glioblastoma cells

add to favorites email to friend print save as pdf

Related Stories

Cancer cures could work for canines and humans

Jul 12, 2007

One of the major issues associated with longer life expectancy in man and his best friend is an increase in the incidence of cancer. Even though they cannot talk it seems dogs might be able to tell us why and how certain ...

Recommended for you

Researcher to cancer: 'Resistance will be futile'

3 hours ago

Turning the tables, Katherine Borden at the University of Montreal's Institute for Research in Immunology and Cancer (IRIC) has evoked Star Trek's Borg in her fight against the disease. "Cancer cells rapidly ...

How does prostate cancer form?

6 hours ago

Prostate cancer affects more than 23,000 men this year in the USA however the individual genes that initiate prostate cancer formation are poorly understood. Finding an enzyme that regulates this process ...

Low risk of malignancy for small complex adnexal masses

12 hours ago

(HealthDay)—For older women with small complex adnexal masses, the overall risk of malignancy is low, according to a study published in the December issue of the American Journal of Obstetrics & Gynecology.

User comments : 0

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.